Maze Therapeutics (NASDAQ:MAZE) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Maze Therapeutics (NASDAQ:MAZE) from a sell rating to a hold rating in a research report report published on Sunday morning.

A number of other brokerages have also weighed in on MAZE. Lifesci Capital upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. BTIG Research increased their price target on Maze Therapeutics from $37.00 to $46.00 and gave the stock a “buy” rating in a report on Friday, January 16th. Guggenheim reaffirmed a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research report on Friday, December 19th. Weiss Ratings reissued a “sell (d)” rating on shares of Maze Therapeutics in a report on Thursday, January 22nd. Finally, HC Wainwright upped their price objective on shares of Maze Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, December 3rd. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $44.50.

Maze Therapeutics Trading Up 1.7%

MAZE opened at $45.34 on Friday. The firm’s fifty day simple moving average is $40.36 and its 200 day simple moving average is $28.57. Maze Therapeutics has a 12 month low of $6.71 and a 12 month high of $47.36. The stock has a market capitalization of $2.18 billion and a P/E ratio of -2.17.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.08.

Insider Activity

In other news, CMO Harold Bernstein sold 25,156 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $40.20, for a total transaction of $1,011,271.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Atul Dandekar sold 72,400 shares of the business’s stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the completion of the sale, the insider owned 10,503 shares in the company, valued at approximately $426,001.68. This trade represents a 87.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 172,500 shares of company stock valued at $7,002,267 in the last 90 days.

Institutional Investors Weigh In On Maze Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in Maze Therapeutics by 218.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock worth $34,615,000 after acquiring an additional 915,342 shares in the last quarter. Marshall Wace LLP raised its stake in Maze Therapeutics by 3,868.5% in the 3rd quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock worth $20,166,000 after acquiring an additional 758,104 shares during the last quarter. ArrowMark Colorado Holdings LLC acquired a new stake in shares of Maze Therapeutics during the third quarter worth about $14,135,000. Frazier Life Sciences Management L.P. boosted its holdings in shares of Maze Therapeutics by 10.6% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock valued at $56,040,000 after acquiring an additional 438,274 shares during the last quarter. Finally, Balyasny Asset Management L.P. acquired a new position in shares of Maze Therapeutics in the 3rd quarter valued at about $11,246,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.